ArticleJournal of the National Cancer Institute2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Article in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.Prostate cancer and prostatic diseases · 2022Trial
- An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines.Current genomics · 2025Review
- Dendritic cell vaccine therapy for colorectal cancer.Pharmacological research · 2021Review
- Landscape of Immunotherapy in Genitourinary Malignancies.Advances in experimental medicine and biology · 2021Review
- Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.JAMA network open · 2019Article
- Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Trends in cancer · 2018Review
- Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8Molecular therapy. Nucleic acids · 2017Article
- Radioligand therapy of metastatic prostate cancer usingOncotarget · 2017Article
- Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2017Article
- Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- The impact of leukapheresis on immune-cell number and function in patients with advanced cancer.Cancer immunology, immunotherapy : CII · 2015Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.Cancer immunology, immunotherapy : CII · 2015Review
- Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.Core evidence · 2015Review
- Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Cancer journal (Sudbury, Mass.)Article
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22825556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.